Posted on March 25th, 2010 by Health News
Pain Therapeutics, Inc. today announced encouraging clinical data with PTI-188, an early-stage drug for metastatic melanoma. Metastatic melanoma is a lethal form of skin cancer in which patients typically have a median survival time of 9 months.
Read more
Filed under: Pharmacy News
Tags: cancer, Drug, Pharmacy, skin cancer, Tumor
Related posts
- GDC-0449 inhibits the Hedgehog signaling pathway (0)
The Hedgehog signaling pathway is involved in a preliminary study and case report describing positive responses to an experimental anticancer drug in a majority of people with advanced or metastatic basal cell skin cancers. One patient with the most common type of pediatric brain cancer, medulloblastoma, also showed tumor shrinkage.
Read more
[tags] Pharmacy News [/tags]
- ZIOPHARM announces new preclinical data from two darinaparsin studies on solid tumors (0)
ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today new preclinical data from two separate studies of darinaparsin, a novel organic arsenic, in various solid tumor models at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.
Read [...]
- Zelboraf receives FDA approval for treatment of metastatic melanoma (0)
The U.S. Food and Drug Administration today approved Zelboraf (vemurafenib), a drug to treat patients with late-stage (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.
Read more
[tags] Pharmacy News [/tags]
- What Protein And Where It Is Located Are Important For Drug Design (0)
Drugs that target a single signaling pathway that drives tumor development and/or progression have been developed successfully to treat a few forms of cancer. However, in many cases drugs designed using this approach have not worked. Dario Altieri and colleagues, at the University of Massachusetts Medical School, Worcester, have now addressed this issue by using [...]
- Two-target approach may effectively stop pancreatic cancer metastasis (0)
Simultaneous targeting of two different molecules in cancer is an effective way to shrink tumors, block invasion, and stop metastasis, scientists at the University of California, San Francisco (UCSF) have found—work that may improve the effectiveness of combination treatments that include drugs like Avastin.
Read more
[tags] Pharmacy News [/tags]
Leave a Reply